| Abstrakt: |
A recent study conducted at the University of Colorado Anschutz Medical Campus has reported new findings on the treatment of solid cancer. The study focused on a novel oral HDAC inhibitor called bocodepsin (OKI-179) and evaluated its safety, pharmacokinetics, pharmacodynamics, and efficacy. The study involved 34 patients with advanced solid tumors who were treated with OKI-179 in different schedules. The researchers found that OKI-179 had a manageable safety profile and showed prolonged disease control in some patients. The study concluded that OKI-179 is currently being investigated in combination with a MEK inhibitor for the treatment of NRAS-mutated melanoma. [Extracted from the article] |
